Paul Sherwin

Publications by Year

Research Areas

Medical Imaging Techniques and Applications, Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Health Systems, Economic Evaluations, Quality of Life, Cerebrospinal fluid and hydrocephalus

Most-Cited Works

• → Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density(2015)331 cited
• → Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads(2014)228 cited
• → Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: The Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial(2008)111 cited
• → Sulfine(1976)102 cited
• → Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection(2016)100 cited
• → Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease(2017)92 cited
• → Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment(2018)85 cited
• → Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging(2000)85 cited
• → [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies(2012)82 cited
• → Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study(2012)75 cited